Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc.

Case: 14-1324 Document: 19 Page: 1 Filed: 05/30/2014 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ ENDO PHARMACEUTICALS INC., Plaintiff-Cross-Appellant, v. MYLAN PHARMACEUTICALS INC. AND MYLAN INC., Defendants-Appellants. ______________________ 2014-1324, -1365 ______________________ Appeals from the United States District Court for the District of Delaware in No. 1:11-cv-00717-RMB-KW, Judge Renee Marie Bumb. --------------------------------------------------------------------- ENDO PHARMACEUTICALS INC., Plaintiff-Appellant, v. MYLAN PHARMACEUTICALS INC. AND MYLAN INC., Defendants-Appellees. ______________________ 2014-1422 Case: 14-1324 Document: 19 Page: 2 Filed: 05/30/2014 2 ENDO PHARMACEUTICALS INC. v. MYLAN PHARMACEUTICALS ______________________ Appeal from the United States District Court for the District of Delaware in No. 1:11-cv-00717-RMB-KW, Judge Renee Marie Bumb. ______________________ ON MOTION ______________________ Before NEWMAN, Circuit Judge. ORDER Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) move without opposition to reactivate and dismiss Appeal Nos. 2014-1324, -1365. Mylan also moves to dismiss certain portions of Endo Pharmaceuticals Inc.’s Appeal No. 2014-1422. Endo opposes dismissal of Appeal No. 2014-1422. These appeals all stem from the same district court action. In Appeal No. 2014-1422, Endo appeals from the district court’s grant of Mylan’s Rule 60(b) motion, which vacated the judgment previously challenged in Appeal Nos. 2014-1324, -1365, as well as other orders. Mylan’s motion seeks to limit Endo’s appeal to the district court’s Rule 60(b) decision. No briefs have yet been filed in this appeal. We deem it the better course for Mylan to raise any issues concern- ing jurisdiction in its brief. Accordingly, IT IS ORDERED THAT: (1) Mylan’s motion to reactivate and dismiss Appeal Nos. 2014-1324, -1365 is granted. Case: 14-1324 Document: 19 Page: 3 Filed: 05/30/2014 ENDO PHARMACEUTICALS INC. v. MYLAN PHARMACEUTICALS 3 (2) Each party shall bear its own costs in Appeal Nos. 2014-1324, -1365. (3) Mylan’s motion to dismiss Appeal No. 2014-1422 is denied. (4) The opening brief in 2014-1422 shall be due no lat- er than June 20, 2014. FOR THE COURT /s/ Daniel E. O’Toole Daniel E. O’Toole Clerk of Court ISSUED AS A MANDATE (As To 14-1324, -1365 Only): May 30, 2014 s30